Hepasonica Arabia | Advancing Ethical & Innovative Pharmaceutical Solutions

Menu

Management Team

At Hepasonica Middle East, our strength lies in the depth of expertise across scientific leadership, strategic advisors, and operational excellence. Our team brings together global minds in heparin science, drug development, regulatory affairs, and pharmaceutical innovation.

Mr. Yiming Yao – Chief Executive Officer

Mr. Yiming Yao – Chief Executive Officer

Founder & President, Suzhou Ronnsi Pharma Co., Ltd.
Mr. Yiming Yao is a seasoned innovator in heparin R&D, holding over 30 academic papers and 10+ patents. He has served in senior roles across North American and Asian pharmaceutical companies, specializing in enzyme catalysis and novel anticoagulant therapies.
About Me
Dr. Xiangping Zhu

Dr. Xiangping Zhu

Deputy General Manager, R&D & Quality
With over two decades of experience in biopharma CMC development and quality, Dr. Zhu has led successful generic and innovative injectable programs. He holds multiple US and EU patents and brings deep expertise in global GMP compliance.
About Me
Mr. Andy Qian

Mr. Andy Qian

Deputy General Manager, Production
Mr. Qian leads production strategy with extensive experience in injectable drug formulation, lyophilization, and global GMP operations. He has contributed to solid and freeze-dried preparations in both Asia and Western regulatory settings.
About Me
Mr. GuoFeng Qi

Mr. GuoFeng Qi

Financial Controller
A certified public accountant with rich experience in IPOs, capital finance, and audit operations. Mr. Qi leads the company’s financial governance, risk control, and strategic fiscal planning.
About Me
Ms. Rose Feng

Ms. Rose Feng

Strategy Consultant
Ms. Feng combines HR leadership with strategic business advisory. Her expertise lies in corporate culture, team performance building, and growth-enabling HR frameworks.
About Me
Dr. YongSheng Jin

Dr. YongSheng Jin

R&D Director
An expert in enzymatic biocatalysis and complex carbohydrate drugs, Dr. Jin oversees product pipeline innovation including ovine-sourced LMWH and heparinoid derivatives. He holds over 10 patents and leads formulation R&D for next-gen injectables.
About Me

Mr. Yiming Yao

Founder and Board Chairman

Mr. Yao has over 30 years of pharmaceutical research and development experience with extensive knowledge in organic synthesis, enzyme catalysis, antibody development, advanced instrumentation, GMP manufacturing and regulatory filing. He has published over 40 scientific papers and more than 20 patents. He leads multiple complex generics and several new drugs development. He founded several biotech companies including Alphamab - a Hongkong stock exchange listed biotech company.